[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100613240":3},{"organization":4,"armGroups":7,"interventions":15,"overallOfficials":21,"centralContacts":26,"locations":21,"responsibleParty":36,"collaborators":21,"id":38,"slug":39,"hasResults":40,"nctId":41,"briefTitle":42,"officialTitle":43,"acronym":21,"eligibilityCriteria":44,"healthyVolunteers":40,"sex":45,"minAge":46,"maxAge":47,"enrollmentInfo":48,"targetDuration":21,"studyType":51,"phases":52,"briefSummary":55,"conditions":56,"keywords":21,"overallStatus":59,"whyStopped":21,"lastUpdateSubmitDate":60,"lastUpdatePostDateStruct":61,"startDateStruct":64,"completionDateStruct":66,"leadSponsor":68,"locationsCount":21},{"fullName":5,"class":6},"Nanfang Hospital, Southern Medical University","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"SORA+VEN","EXPERIMENTAL","sorafenib combined with venetoclax",[13,14],"Drug: Sorafenib (SORA)","Drug: Venetoclax (VEN)",[16,22],{"type":17,"name":18,"description":19,"armGroupLabels":20,"otherNames":21},"DRUG","Sorafenib (SORA)","Sorafenib (SORA) was administered at 400mg twice daily on days 1 to 28.",[9],null,{"type":17,"name":23,"description":24,"armGroupLabels":25,"otherNames":21},"Venetoclax (VEN)","Venetoclax (VEN) was administered at 400mg\u002Fday on days 1 to 28.",[9],[27,32],{"name":28,"role":29,"phone":30,"phoneExt":21,"email":31},"Qifa Liu","CONTACT","+86-020-62787883","liuqifa628@163.com",{"name":33,"role":29,"phone":34,"phoneExt":21,"email":35},"Pengcheng Shi","+86-020-61641615","shpch283@163.com",{"type":37,"investigatorFullName":21,"investigatorTitle":21,"investigatorAffiliation":21,"oldNameTitle":21,"oldOrganization":21},"SPONSOR","100613240","phase-2-sorafenib-combined-with-venetoclax-as-pre-emptive-therapy-strategy-for-mrd-aml-a-prospective-single-arm-multicenter-clinical-study-100613240",false,"NCT07264010","Sorafenib Combined With Venetoclax as Pre-emptive Therapy Strategy for MRD+ AML: a Prospective, Single-arm, Multicenter Clinical Study","Sorafenib Combined With Venetoclax as Pre-emptive Therapy Strategy for Measurable Residual Disease Persisting Acute Myeloid Leukemia: a Prospective, Single-arm, Multicenter Clinical Study","Inclusion Criteria:\n\n* Voluntary signing of informed consent form;\n* Liver and kidney function: Blood bilirubin ≤ 35 μ mol\u002FL, AST\u002FALT \\\u003C 2 times the upper limit of normal, blood creatinine ≤ 150 μ mol\u002FL;\n* Normal heart function (EF ≥ 50%, NYHA I\u002FII);\n* Physical condition score 0-2 (ECOG score);\n* Non pregnant and lactating women. For all women of childbearing age, a pregnancy test must be conducted to determine hCG levels in order to exclude pregnancy status;\n* For all men of childbearing age, contraceptive measures must be taken during sorafenib treatment until 3 months after discontinuation.\n\nExclusion Criteria:\n\n* Acute promyelocytic leukemia;\n* Hematological non-remisssion or recurrence;\n* Uncontrolled infection or grade 3-4 graft-versus-host disease (GVHD);\n* Allergies or contraindications to any of the drugs involved in the protocol;\n* Severe organ dysfunction such as heart, liver, kidneys, lungs, etc.","ALL","18 Years","65 Years",{"count":49,"type":50},87,"ESTIMATED","INTERVENTIONAL",[53,54],"PHASE2","PHASE3","The purpose of this study is to explore the efficacy and safety of sorafenib combined with venetoclax as pre-emptive therapy strategy for measurable residual disease persisting acute myeloid leukemia.",[57,58],"Acute Myeloid Leukaemia (AML)","Measurable Residual Disease (MRD)","NOT_YET_RECRUITING","2025-11-23",{"date":62,"type":63},"2025-12-04","ACTUAL",{"date":65,"type":50},"2025-12-01",{"date":67,"type":50},"2028-12-30",{"name":5,"class":6}]